Madrigal Pharmaceuticals MDGL
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Madrigal Pharmaceuticals (MDGL) Core Market Data and Business Metrics
Latest Closing Price
$334.6Price-Earnings Ratio
-15.28Total Outstanding Shares
22.08 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
200 Barr Harbor Drive, Suite 400, West Conshohocken, PA, 19428
Historical Stock Splits
If you bought 35 shares of MDGL before July 25, 2016, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| July 25, 2016 | 1-for-35 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 479,995 Shares | 8.53 | 3/14/2025 | 4,094,246 Shares |
| 431,065 Shares | 8.71 | 2/28/2025 | 3,753,213 Shares |
| 354,573 Shares | 10.7 | 2/14/2025 | 3,795,295 Shares |
| 465,120 Shares | 8.56 | 1/31/2025 | 3,982,712 Shares |
| 454,640 Shares | 8.98 | 1/15/2025 | 4,083,736 Shares |
| 325,210 Shares | 12.63 | 12/31/2024 | 4,106,529 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $735.06 Million |
| Net Cash Flow From Investing Activities | $-274.39 Million |
| Net Cash Flow From Investing Activities, Continuing | $-274.39 Million |
| Net Cash Flow From Operating Activities | $-455.57 Million |
| Net Cash Flow, Continuing | $5.10 Million |
| Net Cash Flow From Financing Activities, Continuing | $735.06 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $-465.89 Million |
| Income Tax Expense/Benefit | $0 |
| Operating Expenses | $671.77 Million |
| Income/Loss From Continuing Operations After Tax | $-465.89 Million |
| Other Operating Expenses | $236.72 Million |
| Basic Average Shares | $21.27 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-465.89 Million |
| Comprehensive Income/Loss | $-465.89 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $1.04 Billion |
| Other Current Assets | $67.61 Million |
| Noncurrent Liabilities | $118.59 Million |
| Accounts Payable | $43.60 Million |
| Current Liabilities | $169.28 Million |
| Long-term Debt | $117.57 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||